The Effectivness of probiotic in the treatment of gastrointestinal symptoms in patients with scleroderma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015120618142N2

Enrollment

Registered

2015-12-25

Start date

2014-04-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

scleroderma. Systemic sclerosis

Interventions

Intervention 1: Intervention group: Probiotics use in form of drug pill. Intervention 2: control: placebo similar to main drug.

Placebo

Treatment - Drugs

Intervention group: Probiotics use in form of drug pill

control: placebo similar to main drug

Eligibility

Sex/Gender

All

Age

18 Years to 57 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with gastrointestinal symptoms moderate to sever Exclusion criteria: non using drug in exact time; non tolerance for drug side effects; non tended to participate in study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Improvement in gastrointestinal symptoms. Timepoint: Baseline-two month late. Method of measurement: Score.	—

Secondary

Measure	Time frame
Improvment in reflux condition , emotional and social function. Timepoint: baseline-after two months. Method of measurement: Score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Afsaneh Enteshari-Moghaddam

Ardabil University of Medical Sciences

afsanehenteshary@gmail.com+98 45 3351 3777

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026